Search results
Showing 1246 to 1260 of 7680 results
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.
Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis. This drug is for adults who have tried nonsteroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.
Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)
Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.
Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic (secondary), oestrogen-receptor positive breast cancer in postmenopausal women who have not had endocrine therapy before.
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
Evidence-based recommendations on nivolumab (Opdivo) for advanced non-squamous non-small-cell lung cancer in adults after chemotherapy.